The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
About this study
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.
- Condition
- Diabetes Mellitus, Type 2
- Sponsor
- University of Athens
Who can join
- Age
- 45 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 45 years
- Maximum age: 80 years
- Study condition: Diabetes Mellitus, Type 2
- Subject has type 2 diabetes mellitus
- Subject has high or very high cardiovascular risk
- Subject has heart failure with preserved ejection fraction
Exclusion 3
- Subject has type 1 diabetes mellitus
- Subject has kidney disease
- Subject has retinopathy
Where
1 site, 1 recruiting
"Attikon" University General Hospital
Athens, Attica, Greece
Contact
-
Ignatios Ikonomidis, Prof.
00306944805732 ignoik@gmail.com
-
Aimilianos N. Kalogeris, MD
00306949630300 kalogeris.cardio@gmail.com
Potential match only. Final eligibility is determined by the study team.